Bivalirudin Doesn't Lower Major Cardiovascular Event Rate in ACS

This article originally appeared here.
Share this content:
Bivalirudin Doesn't Lower Major Cardiovascular Event Rate in ACS
Bivalirudin Doesn't Lower Major Cardiovascular Event Rate in ACS

TUESDAY, Sept. 1, 2015 (HealthDay News) -- For patients with an acute coronary syndrome undergoing percutaneous coronary intervention (PCI), bivalirudin does not lower the rates of major adverse cardiovascular events, according to a study published online Sept. 1 in the New England Journal of Medicine. The research was published to coincide with the annual European Society of Cardiology Congress, held from Aug. 29 to Sept. 2 in London.

Marco Valgimigli, M.D., Ph.D., from Bern University Hospital in Switzerland, and colleagues randomized 7,213 patients with an acute coronary syndrome for whom PCI was anticipated to receive bivalirudin or unfractionated heparin. Patients in the bivalirudin group were then randomized to receive a post-PCI bivalirudin infusion, or not.

The researchers found that the rates of major cardiovascular events (P = 0.44) and net adverse clinical events (P = 0.12) were not significantly lower with bivalirudin versus heparin. Compared with no infusion, post-PCI bivalirudin infusion was not associated with a significant decrease in the rate of urgent target-vessel revascularization, definite stent thrombosis, or net adverse clinical events (P = 0.34).

"In patients with an acute coronary syndrome, the rates of major adverse cardiovascular events and net adverse clinical events were not significantly lower with bivalirudin than with unfractionated heparin," the authors write. "The rate of the composite of urgent target-vessel revascularization, definite stent thrombosis, or net adverse clinical events was not significantly lower with a post-PCI bivalirudin infusion than with no post-PCI infusion."

Several authors disclosed financial ties to pharmaceutical and medical device companies, including the Medicines Company (which manufactures bivalirudin) and Terumo Medical, both of which funded the study.

Abstract
Full Text
Editorial
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

CDC: Too Many Health Care Workers Not Getting Flu Vaccine

CDC: Too Many Health Care Workers Not Getting ...

Vaccination protects both workers and patients

Early Mobilization Improves Outcomes, LOS in Surgical ICUs

Early Mobilization Improves Outcomes, LOS in Surgical ICUs

Patients discharged sooner, become more functional when they leave the hospital

is free, fast, and customized just for you!

Already a member?

Sign In Now »